Skip to content

Rheumatoid arthritis — extra-articular and comorbid disease

TL;DR — RA is systemic: cardiovascular disease, infection, osteoporosis/fracture, lung disease, eye inflammation, neuropathy, nodules, cytopenias and rarely vasculitis materially alter prognosis. These outcomes reflect overlapping contributions from inflammation, autoimmunity, smoking, age, organ damage and treatment. A 2024 mortality meta-analysis spanning 486,098 patients and 63,988 deaths confirmed excess all-cause and cause-specific mortality (Lee 2024, PMID 38918258). Low-dose glucocorticoids are not benign: large cohorts find a dose-dependent increase in hospitalized infection even at ≤5 mg/day prednisone equivalent (George 2020, PMID 32956604). Comorbidity work is part of RA control, not an optional add-on.

Manifestation map

System RA-associated problem High-consequence clue
Cardiovascular accelerated atherosclerotic events, heart failure, pericardial disease chest pain, dyspnea, focal neurologic deficit
Pulmonary ILD, nodules, airway disease, pleuritis new exertional dyspnea, cough, hypoxemia
Eye sicca, episcleritis, scleritis, peripheral ulcerative keratitis painful red eye or visual change
Neurologic entrapment neuropathy, vasculitic neuropathy, cervical myelopathy weakness, gait change, sphincter symptoms
Skin nodules, ulcers, vasculitis, drug eruptions necrosis, palpable purpura, infected ulcer
Hematologic anemia, cytopenia, Felty syndrome, large granular lymphocyte overlap neutropenic fever
Bone periarticular loss, generalized osteoporosis, fragility fracture height loss, acute back/hip pain
Infection bacterial, zoster, opportunistic infections fever may be blunted by immunosuppression

Cardiovascular disease

Inflammation and conventional risk factors interact. Meta-analyses document increased symptomatic and subclinical cardiovascular disease, while comparative observational studies suggest effective inflammation control may reduce risk (Restivo 2022, PMID 34454117; Singh 2020, PMID 30875456).

Assessment Why it matters
Smoking Joint, lung and cardiovascular risk
Blood pressure Common, modifiable and steroid-sensitive
Lipids Inflammation and IL-6/JAK therapy alter levels
Diabetes/weight Raises absolute event and infection risk
Disease activity Cumulative inflammation contributes to risk
Drug choice NSAIDs, glucocorticoids and JAK inhibitors alter risk frame

Risk calculators can underestimate inflammatory-disease risk; country-specific guidance should determine adjustments. ORAL Surveillance makes established cardiovascular risk central when choosing a JAK inhibitor (Ytterberg 2022, PMID 35081280).

Infection

RA patients had greater serious-infection risk than people with non-inflammatory musculoskeletal disease in a US national cohort (Mehta 2019, PMID 31245055). Disease, age, lung disease, diabetes, frailty, glucocorticoids and each DMARD mechanism contribute.

Risk amplifier Action domain
Glucocorticoid dose/duration Minimize and taper
Recurrent respiratory infection Lung evaluation and vaccination
Rituximab HBV plan; immunoglobulin/vaccine timing
TNF inhibition TB and hepatitis screening
JAK inhibition Zoster vaccination and risk stratification
Neutropenia Drug attribution and urgent fever pathway

George et al. studied stable-DMARD RA cohorts in Medicare and Optum data and found dose-dependent hospitalized infection risk with long-term glucocorticoids, including low dose (George 2020, PMID 32956604). This supports steroid-sparing even when daily dose appears small.

Osteoporosis and fracture

Inflammation, reduced loading, menopause/age, low body mass, falls and glucocorticoids converge. Meta-analyses confirm increased overall and fragility fracture risk (Xue 2017, PMID 28885321; Jin 2018, PMID 29546507). RA is included as a FRAX clinical risk factor; updated individual-person meta-analysis across 29 cohorts confirmed excess fracture risk in men and women (Kanis 2025, PMID 39955689).

Prevention element Evidence-informed purpose
Minimize glucocorticoids Reduce dose-dependent bone/infection harm
BMD and fracture-risk assessment Identify treatment thresholds
Falls and strength assessment Address non-BMD fracture pathway
Calcium/vitamin D adequacy Correct deficiency; not sole therapy at high risk
Antiresorptive/anabolic therapy Based on absolute fracture risk and guideline
Inflammation control Reduce systemic bone resorption and improve mobility

Eye, skin, nerve and vasculitis

Ocular meta-analysis documents sicca and inflammatory eye manifestations; scleritis and peripheral ulcerative keratitis can threaten vision (Turk 2021, PMID 32358156). Rheumatoid nodules associate with seropositive disease and may be accelerated by methotrexate in some cases.

Rheumatoid vasculitis is now rarer but remains severe, usually in longstanding seropositive disease. Skin and peripheral nerves are frequent targets; mononeuritis multiplex, digital ischemia, ulcers or systemic inflammation require urgent evaluation (Mertz 2023, PMID 37468085; de Cerqueira 2021, PMID 33058033).

Reproductive health

RA commonly affects people of childbearing age. Methotrexate and leflunomide require preconception planning; agent-specific pregnancy and breastfeeding compatibility differs. Disease activity itself affects pregnancy outcomes, so stopping all therapy can be harmful. Reviews comparing reproductive guidance emphasize planned transitions rather than abrupt withdrawal (Murray 2019, PMID 29748892; Chin 2025, PMID 40256995).

Interpretation rule

Attribution should remain explicit: a complication can arise from RA biology, conventional risk factors, organ damage, treatment, or their interaction.

Quantified comorbidity gradients

Domain Estimate Interpretation
Cardiovascular events In 17 cohorts (124,894 patients), MI incidence-rate ratio was 2.10 (95% CI 1.52–2.89) and stroke incidence-rate ratio 1.91 (1.73–2.12); fatal-event SMRs were 1.77 and 1.46 (Meune 2010, PMID 20656636). Traditional risk, inflammation, treatment, and surveillance all contribute; RA is a risk enhancer, not a complete risk equation.
Depression Major depressive disorder prevalence 16.8% (95% CI 10–24); instrument-defined estimates ranged 14.8–38.8% (Matcham 2013, PMID 24003249). Screening thresholds and clinical diagnosis must not be conflated.
Malignancy A broad meta-analysis found cancer patterns differ by site rather than a uniform increase (Simon 2015, PMID 26271620); older autoimmune-disease meta-analysis supported a lymphoma excess (Zintzaras 2005, PMID 16287762). Disease activity, smoking, prior treatment, and detection bias confound attribution.
Anti-TNF and lymphoma Contemporary systematic review found no clear statistically significant increase versus conventional treatment, but confidence intervals remained compatible with clinically relevant differences (Imam 2024, PMID 39064585). “No significant association” is not proof of no rare risk.
Pregnancy Nine studies with 11,999 RA pregnancies found OR 1.55 for cesarean delivery, 1.61 for pre-eclampsia, 1.83 for preterm delivery and 1.99 for stillbirth; neonatal weight difference −0.19 kg (Sim 2023, PMID 36544253). Activity, medication, age, parity and comorbidity are incompletely separated.
Neurologic disease Systematic review documents central and peripheral nervous-system manifestations but emphasizes heterogeneous case definitions and immune profiles (Bougea 2015, PMID 26688829). Entrapment neuropathy, vasculitis, cervical myelopathy and drug toxicity require different pathways.

Methotrexate exposure is associated with fewer cardiovascular events in observational synthesis (Sun 2021, PMID 33607787), but this may reflect control of inflammation or selection of healthier, adherent patients rather than a direct cardioprotective drug effect. The competing safety concern is glucocorticoid exposure, which contributes infection, fracture, metabolic and vascular risk even at doses often called “low.” Comorbidity management should therefore be treated as a parallel disease-modifying strategy rather than deferred until joint remission.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations, pathogenesis and management. Eur Respir Rev. 2021. (PMID 34168062) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, ra-associated-interstitial-lung-disease.md, red-flags-and-safety-concerns.md
Sullivan DI, et al. RA-ILD update on prevalence, risk factors, pathogenesis and therapy. 2024. (PMID 39320427) Adjacent evidence from ra-associated-interstitial-lung-disease.md
Kim Y, et al. Etiology and pathogenesis of rheumatoid arthritis-interstitial lung disease. 2023. (PMID 37833957) Adjacent evidence from genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, ra-associated-interstitial-lung-disease.md
Saavedra AA, et al. RA-ILD treatment: appraisal of 2023 ACR/CHEST guideline. 2025. (PMID 39822854) Adjacent evidence from conventional-dmards.md, guidelines.md, ra-associated-interstitial-lung-disease.md, treat-to-target-and-remission.md
Yao C, et al. RA-ILD clinical predictive model and external validation. 2025. (PMID 41299487) Adjacent evidence from ra-associated-interstitial-lung-disease.md
Krishna Boppana T, et al. Rituximab for RA-related ILD: systematic review and meta-analysis. 2024. (PMID 38933731) Adjacent evidence from ra-associated-interstitial-lung-disease.md
Provan SA, et al. ILD in RA or PsA initiating biologics: five Nordic registries. 2024. (PMID 39218450) Adjacent evidence from ra-associated-interstitial-lung-disease.md
Cassone G, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020. (PMID 32290218) Adjacent evidence from epidemiology-and-burden.md, ra-associated-interstitial-lung-disease.md
Narváez J, et al. JAK inhibitors in RA-associated ILD: systematic review and meta-analysis. 2024. (PMID 39270812) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, ra-associated-interstitial-lung-disease.md
Earwood JS, et al. Septic arthritis: diagnosis and treatment. Am Fam Physician. 2021. (PMID 34913662) Adjacent evidence from red-flags-and-safety-concerns.md
Margaretten ME, et al. Does this adult patient have septic arthritis? JAMA. 2007. (PMID 17405973) Adjacent evidence from red-flags-and-safety-concerns.md
Shlobin NA, et al. Cervical spine manifestations of rheumatoid arthritis: review. Neurosurg Rev. 2021. (PMID 33037539) Adjacent evidence from red-flags-and-safety-concerns.md
Joaquim AF, et al. Cervical spine involvement in RA: systematic review. Autoimmun Rev. 2014. (PMID 25151973) Adjacent evidence from red-flags-and-safety-concerns.md
Friedman MA, et al. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016. (PMID 26986246) Adjacent evidence from red-flags-and-safety-concerns.md
GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050. Lancet Rheumatol. 2023. (PMID 37795020) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md
Safiri S, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017. Ann Rheum Dis. 2019. (PMID 31511227) Adjacent evidence from epidemiology-and-burden.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • How much cardiovascular excess persists after sustained remission and modern risk-factor treatment?
  • What steroid dose-duration combination produces clinically important infection risk in younger patients? (George 2020, PMID 32956604)
  • Which RA populations need systematic vertebral imaging? (Jin 2018, PMID 29546507)
  • Why has rheumatoid vasculitis declined, and which cases remain treatment-related or biologically distinct? (Mertz 2023, PMID 37468085)
  • Can one coordinated comorbidity review improve mortality rather than process measures alone?

References

  1. Lee YH, et al. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024;83:314-320. PMID 38918258
  2. George MD, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med. 2020;173:870-878. PMID 32956604
  3. Restivo V, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21:102925. PMID 34454117
  4. Singh S, et al. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020;72:561-576. PMID 30875456
  5. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  6. Mehta B, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5:e000935. PMID 31245055
  7. Xue AL, et al. Bone fracture risk in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2017;96:e6983. PMID 28885321
  8. Jin S, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018;29:1263-1275. PMID 29546507
  9. Kanis JA, et al. Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int. 2025;36:653-671. PMID 39955689
  10. Turk MA, et al. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol. 2021;48:25-34. PMID 32358156
  11. Mertz P, et al. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev. 2023;22:103391. PMID 37468085
  12. de Cerqueira DPA, et al. Biological therapy in rheumatoid vasculitis: a systematic review. Clin Rheumatol. 2021;40:1717-1724. PMID 33058033
  13. Murray KE, et al. Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. Ir J Med Sci. 2019;188:169-172. PMID 29748892
  14. Chin A, et al. Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). 2025;77:1273-1281. PMID 40256995
  15. Meune C, et al. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. PMID 20656636
  16. Matcham F, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52:2136-48. PMID 24003249
  17. Simon TA, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212. PMID 26271620
  18. Zintzaras E, et al. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-44. PMID 16287762
  19. Imam AA, et al. Anti-TNF Alpha and Risk of Lymphoma in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2024;60:1156. PMID 39064585
  20. Sim BL, et al. Pregnancy Outcomes in Women With Rheumatoid Arthritis: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2023;29:36-42. PMID 36544253
  21. Bougea A, et al. A Systematic Review of Peripheral and Central Nervous System Involvement of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, and Associated Immunological Profiles. Int J Chronic Dis. 2015;2015:910352. PMID 26688829
  22. Sun KJ, et al. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis. Medicine (Baltimore). 2021;100:e24579. PMID 33607787
  23. Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. PMID 34168062
  24. Sullivan DI, et al. Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy. Curr Rheumatol Rep. 2024;26:431-449. PMID 39320427
  25. Kim Y, et al. Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. Int J Mol Sci. 2023;24:14509. PMID 37833957
  26. Saavedra AA, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. Curr Treatm Opt Rheumatol. 2024;10:43-60. PMID 39822854
  27. Yao C, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical predictive model and external validation. Respir Res. 2025;26:331. PMID 41299487
  28. Krishna Boppana T, et al. Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis. Arch Rheumatol. 2024;39:317-329. PMID 38933731
  29. Provan SA, et al. Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries. J Rheumatol. 2024;51:1111-1118. PMID 39218450
  30. Cassone G, et al. Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. J Clin Med. 2020;9:1082. PMID 32290218
  31. Narváez J, et al. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2024;23:103636. PMID 39270812
  32. Earwood JS, et al. Septic Arthritis: Diagnosis and Treatment. Am Fam Physician. 2021;104:589-597. PMID 34913662
  33. Margaretten ME, et al. Does this adult patient have septic arthritis?. JAMA. 2007;297:1478-88. PMID 17405973
  34. Shlobin NA, et al. Cervical spine manifestations of rheumatoid arthritis: a review. Neurosurg Rev. 2021;44:1957-1965. PMID 33037539
  35. Joaquim AF, et al. Cervical spine involvement in rheumatoid arthritis--a systematic review. Autoimmun Rev. 2014;13:1195-202. PMID 25151973
  36. Friedman MA, et al. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28:330-6. PMID 26986246
  37. GBD 2021 Rheumatoid Arthritis Collaborators Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594-e610. PMID 37795020
  38. Safiri S, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78:1463-1471. PMID 31511227